Scholars@Duke
construction release_alert
Scholars@Duke will be down for maintenance for approximately one hour starting Tuesday, 11/11 @1pm ET
cancel
Russell Dean Anderson

Russell Dean Anderson

Assistant Professor of Medicine
Medicine, Medical Oncology
russell.anderson@duke.edu
Duke Box 3395, Durham, NC 27708
Johnston Cancer Center, Smithfield, NC 27577

Selected Publications

"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.

Journal Article Biol Blood Marrow Transplant · January 2010 The purpose of this study was to evaluate the efficacy and safety of short-course bortezomib, melphalan, prednisone (VMP) in previously untreated multiple myeloma as frontline therapy for transplant-ineligible patients and induction prior to autologous ste ... Full text Link to item Cite

Correlation of doxorubicin footprints with deletion endpoints in lacO of E. coli.

Journal Article Mutat Res · January 1995 This study explored the possibility that the sequence location of doxorubicin-induced deletion endpoints might relate to DNA structural alterations caused by doxorubicin binding to DNA. The 3'-OH endpoints of doxorubicin-induced deletions terminating in th ... Full text Link to item Cite

Effect of isopropyl-beta-D-thiogalactopyranosid induction of the lac operon on the specificity of spontaneous and doxorubicin-induced mutations in Escherichia coli.

Journal Article Environ Mol Mutagen · 1995 Previous studies of doxorubicin-induced mutations employing F' lacl/lacO as an endogenous gene target have focused on properties of large deletions with 3' endpoints residing in the lacO region of the target gene. This study considers the influence of Lac ... Full text Link to item Cite

International Commission for Protection Against Environmental Mutagens and Carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents.

Journal Article Mutat Res · August 1, 1994 Drugs that interact with DNA topoisomerases I and II hold great promise for the treatment of cancer, however, like many other anti-cancer agents, they are a double-edged sword and may themselves cause mutation and cancer. In vitro studies show that clinica ... Full text Link to item Cite

Excision repair reduces doxorubicin-induced genotoxicity.

Journal Article Mutat Res · October 1993 LacI mutations induced by doxorubicin in a wild-type, uvr(A)BC repair-proficient E. coli strain were analyzed by DNA sequencing. These mutations were contrasted with mutations previously recovered from doxorubicin-treated uvrB- organisms in order to assess ... Full text Link to item Cite

Sequencing of double-stranded polymerase chain reaction products for mutation analysis.

Journal Article Mutat Res · July 1993 This report describes a reproducible, straightforward approach to sequencing double-stranded DNA products from the polymerase chain reaction (PCR) for analysis of mutations. The sequencing protocol is a modification of that published by Kretz (Kretz et al. ... Full text Link to item Cite

DNA sequence specificity of doxorubicin-induced mutational damage in uvrB- Escherichia coli.

Journal Article Cancer Res · August 1, 1991 In the absence of excision repair, doxorubicin caused a striking (41-fold) increase in the frequency of large deletion mutations extending from the lac operator (lacO) into the lac repressor gene (lacI) of Escherichia coli. In contrast, there was only a 2- ... Link to item Cite